Related Experiment Video
Updated: Feb 21, 2026

07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
15.3K
Treatment challenges in and outside a network setting: Soft tissue sarcomas
Sandro Pasquali1, Sylvie Bonvalot2, Dimitri Tzanis2
1Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Summary
Patients with soft tissue sarcoma (STS) fare better when treated at specialized centers following guidelines. Many patients, especially early-stage surgical cases, do not receive guideline-adherent care, highlighting a need for improved clinical pathways.
Area of Science:
- Oncology
- Surgical Oncology
- Health Services Research
Background:
- Soft tissue sarcoma (STS) patient outcomes are significantly better when treated at specialized institutions or within dedicated networks, adhering to clinical practice guidelines.
- Despite evidence, a substantial proportion of STS patients, particularly those requiring early-stage surgery, do not receive guideline-adherent care.
- The definition and certification of expert institutions based on criteria like treatment volume remain debated, impacting patient management and research.
Purpose of the Study:
- To discuss challenges in soft tissue sarcoma (STS) management, including pathological diagnosis and guideline adherence.
- To explore the definition and establishment of specialized referral centers and treatment networks for STS.
- To review existing experiences and population-based data regarding STS patient management pathways.
Main Methods:
- Review of existing clinical practice guidelines for soft tissue sarcoma (STS) management.
- Analysis of population-based data and existing experiences with sarcoma specialized units and treatment networks.
- Discussion of pathological diagnostic criteria and adherence to treatment protocols.
Main Results:
- Patients treated according to guidelines at specialized centers or networks demonstrate improved outcomes.
- A significant gap exists in guideline adherence for STS patients, especially in early-stage surgical management.
- The identification and networking of expert centers are emerging but require further development and standardization.
Conclusions:
- Improving clinical pathways for soft tissue sarcoma (STS) patients through adherence to guidelines and specialized care is a priority for health authorities.
- Establishing and certifying expert centers and treatment networks are crucial for enhancing patient outcomes and fostering clinical research innovation.
- Addressing issues in pathological diagnosis and guideline adherence is essential for optimizing STS patient management.
Related Concept Videos
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K

